Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26553730 | 0.94 | ADORA2A (0.51) | PRMT6ADORA3ADORA2AADORA2B | |
| SCHEMBL18464846 | 0.87 | PRMT6 (0.53) | PRMT6ADORA3ADORA2AADORA2B | |
| SCHEMBL26553789 | 0.87 | PRMT6 (0.53) | PRMT6ADORA3ADORA2AADORA2B | |
| SCHEMBL25765149 | 0.87 | PRMT6 (0.53) | PRMT6ADORA3 | |
| SCHEMBL26554294 | 0.87 | PRMT6 (0.48) | PRMT6ADORA3ADORA2AADORA2B | |
| SCHEMBL26553794 | 0.87 | PRMT6 (0.53) | PRMT6ADORA3 | |
| SCHEMBL10889457 | 0.84 | ADORA3 (0.58) | AHCYADORA3ADORA2AADORA2B | |
| SCHEMBL12700006 | 0.83 | PRMT6 (0.54) | PRMT6ADORA3ADORA2AADORA2B | |
| SCHEMBL1582757 | 0.81 | MEN1 (0.63) | ADORA3ADORA2AADORA2B | |
| SCHEMBL20454454 | 0.81 | MEN1 (0.63) | ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | PRMT6 1699/4885AHCY 3101/4885ADORA3 1358/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | PRMT6 1699/4885AHCY 3101/4885ADORA3 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.